60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
08 févr. 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
Kristen Landon appointed Chief Commercial Officer at 60 Degrees Pharma leading ARAKODA® relaunch for malaria prevention and expanded tick-borne strategy.
Gallant Therapeutics Adds Animal Health Executive Aaron Schacht to Board of Directors
06 févr. 2024 08h10 HE
|
Gallant Therapeutics
Gallant Therapeutics Adds Animal Health Executive Aaron Schacht to Board of Directors
Knight Therapeutics Announces Launch of Bijuva® in Canada
06 févr. 2024 07h30 HE
|
Knight Therapeutics
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA®...
Digital Therapeutics Market / DTx Market is Expected to Reach $21.9 Billion | MarketsandMarkets™
02 févr. 2024 07h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Digital Therapeutics Market / DTx market in terms of revenue was estimated to be worth $6.1 billion in 2023 and is poised to reach $21.9 billion by 2028,...
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
31 janv. 2024 11h15 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals (Nasdaq: SXTP) closes $2.4 million public offering.
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
30 janv. 2024 09h00 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma announces a $2.4 mil public offering, with funds to be used for working capital, relaunching ARAKODA for malaria prevention, and research
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
29 janv. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
25 janv. 2024 07h30 HE
|
Knight Therapeutics
MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an...
Recombinant Proteins Market revenue to hit USD 9 Billion by 2035, says Research Nester
25 janv. 2024 05h30 HE
|
Research Nester
New York, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The global recombinant proteins market size is slated to expand at ~12.80% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 9...
Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts
23 janv. 2024 08h00 HE
|
ProPhase Labs, Inc.
Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and ProfitabilityCompany in Late-Stage Discussions with Two Additional Large Global Brands...